Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer by Marise R. Heerma van Voss et al.
ORIGINAL PAPER
Expression of the stem cell marker ALDH1 in BRCA1
related breast cancer
Marise R. Heerma van Voss & Petra van der Groep &
Joost Bart & Elsken van der Wall & Paul J. van Diest
Accepted: 11 December 2010 /Published online: 19 February 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Introduction The BRCA1 protein makes mammary stem
cells differentiate into mature luminal and myoepithelial
cells. If a BRCA1 mutation results in a differentiation
block, an enlarged stem cell component might be present in
the benign tissue of BRCA1 mutation carriers, and these
mammary stem cells could be the origin of BRCA1 related
breast cancer. Since ALDH1 is a marker of both mammary
stem cells and breast cancer stem cells, we compared
ALDH1 expression in malignant tissue of BRCA1 mutation
carriers to non-carriers.
Methods Forty-one BRCA1 related breast cancers and 41
age-matched sporadic breast cancers were immunohisto-
chemically stained for ALDH1. Expression in epithelium
and stroma was scored and compared.
Results Epithelial (P=0.001) and peritumoral (P=0.001)
ALDH1 expression was significantly higher in invasive
BRCA1 related carcinomas compared to sporadic carcino-
mas. Intratumoral stromal ALDH1 expression was similarly
high in both groups. ALDH1 tumor cell expression was an
independent predictor of BRCA1 mutation status.
Conclusion BRCA1 related breast cancers showed signifi-
cantly more frequent epithelial ALDH1 expression, indi-
cating that these hereditary tumors have an enlarged cancer
stem cell component. Besides, (peritumoral) stromal
ALDH1 expression was also more frequent in BRCA1
mutation carriers. ALDH1 may therefore be a diagnostic
marker and a therapeutic target of BRCA1 related breast
cancer.
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1 Introduction
Germline mutation carriers of the BRCA1 gene locus
harbor a high cumulative risk of developing breast and
ovarian cancer of 57% and 40% by age 70, respectively [1].
BRCA1 related breast cancer shows a distinct histopatho-
logical and immunohistochemical phenotype. It has been
shown to be more often of the ductal or medullary types, of
high grade and to show a high mitotic activity index (MAI)
and necrosis [2–4]. These tumors usually do not express the
estrogen (ER) and progesterone receptors (PR) and are
almost always HER-2/neu negative (“triple negative”) [2,
3]. At the gene-expression level these tumors cluster
together with the basal-like subgroup [5]. BRCA1 seems
to play an important role in DNA repair in a common
pathway with BRCA2 [6]. Increasing evidence indicates
that BRCA1 is necessary for mammary stem cell differen-
tiation, a function that could explain its tissue-specificity
[7–10].
Stem cells play a role in repopulating the breast at
several points in the human female lifespan. These
primitive cells facilitate rapid expansion and regression in
puberty and pregnancy, and during the menstrual cycle. In
recent studies mammary stem cells have been isolated, by
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evaluation of specific characteristics like multipotency, the
ability to undergo both symmetrical and asymmetrical
divisions and being long-lived, slow cycling cells [11, 12].
A hierarchy of epithelial cells does not only seem to be
present in the normal mammary gland, but in tumors as
well. Al-Hajj et al. showed that only a small subpopulation
of all cells in a tumor could be serially passaged, indicative
of their tumor initiating capacity. These cells share many
characteristics with stem cells, and are therefore denoted
cancer stem cells (CSC) [13]. These CSCs could be
important therapy targets, due to their tumor initiating
capacity and being therapy resistant.
Several markers have been identified for the selection
of human (cancer) stem cells, of which Aldehyde
dehydrogenase 1 (ALDH1) is among the most widely
studied ones. ALDH1 is a cytosolic detoxifying enzyme
responsible for the oxidation of (retin)aldehydes into
retinoids [14], which has been put forward as a marker of
both normal human mammary stem cells and breast cancer
stem cells. Human mammary cells selected for increased
ALDH1 activity had the broadest lineage differentiation
potential and highest growth capacity in a xenograft
model, indicating that the ALDH1 positive cell population
is enriched for mammary stem cells. Furthermore, it was
shown that the ALDH1 positive population showed high
tumorigenic capacity through serial passages, in contrast
with the ALDH1 negative population [15]. The exact
function of ALDH1 in (mammary) stem cells remains
largely unknown, but it is thought to play a role in cellular
differentiation, mainly through the retinoid signaling
pathway [16].
As mentioned above, a novel function subscribed to
BRCA1 is the regulation of mammary stem cell differen-
tiation. An association between BRCA1 and stem cells was
first suspected because of the basal phenotype of BRCA1
related tumors which resembles that of primitive mammary
cells, implying that BRCA1 related tumors might originate
in stem cells [17]. In vitro experiments have shown that
ectopic overexpression of BRCA1 increases differentiation,
whereas reduction of endogenous BRCA1 impairs differ-
entiation [8]. Knockdown of BRCA1 in primary breast
epithelial cells leads to accumulation of cells expressing
ALDH1 and a decrease in ER positive cells expressing
luminal epithelial markers. Furthermore, in the normal
tissue of BRCA1 mutation carriers, clusters of ALDH1
positive cells have been described that were ER negative
and showed loss of heterozygosity (LOH) of BRCA1.
These results indicate that BRCA1 might indeed serve as a
stem cell regulator in the mammary epithelium and that the
stem cell pool in the normal tissue of BRCA1 mutation
carriers might be enlarged [9], although our own results
contradicted this [18]. If the origin of BRCA1 related
cancer lies in this pool of stem cells, we would expect
characteristics of this stem cell population like ALDH1 to
be reflected in BRCA1 related breast cancers. In this study
we therefore evaluated ALDH1 expression in invasive
breast carcinomas of BRCA1 mutation carriers in compar-
ison with cancers of non-carriers.
2 Methods
2.1 Study population
An invasive carcinoma group composed of 41 BRCA1
germline mutation carriers was age-matched with a control
group, aiming at a maximum age difference of 5 years
between case and control. We excluded all cases that
mentioned a strong family history of breast cancer in the
pathology report and all cases of which cumulative breast
cancer risk exceeded 30% based on family history [19], but
included patients that were referred to Clinical Genetics
because of the young age of onset only and tested negative
for BRCA1/2 mutations. This control group is further
denoted “sporadic”. Anonymous use of redundant tissue for
research purposes is part of the standard treatment
agreement with patients in our hospitals [20]. Clinical data
were retrieved from the pathology report and patient files.
MAI was assessed as before [21]. Growth pattern was
classified as expansive if pushing margins were observed
in >50% of the tumor circumference, and otherwise as
infiltrative [22].
2.2 Immunohistochemistry
Immunohistochemical analysis was carried out on 4-μm
sections. All stainings were performed on full slides to
avoid false negatives due to tumor heterogeneity. For all
stainings, slides were deparaffinized in xylene and rehy-
drated in decreasing ethanol dilutions. Endogenous perox-
idase activity was blocked with a buffer containing
peroxide, followed by antigen retrieval. A cooling off
period of 30 min preceded incubation with the primary
antibody. Primary antibodies used, incubation time and the
method of antigen retrieval are summarized in Table 1. In
the case of EGFR we followed the protocol of the Pharm
Dx kit. For all other antibodies, detection was done with a
poly HRP anti Mouse/Rabbit/Rat IgG (ready to use;
Powervision, Immunologic, Immunovision Technologies,
Brisbane, California, USA). Peroxidase activity was devel-
oped with diaminobenzidin, except for ALDH1 for which
we used Nova Red (Vector laboratories, Burlingame, USA).
Slides were finally lightly counter-stained with hematoxylin
and mounted. In between steps, slides were washed in PBS.
Appropriate negative and positive controls were used
throughout.
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Staining for ER, PR, HER-2/neu, cytokeratin 5/6 (CK5/6)
and epidermal growth factor receptor (EGFR) was per-
formed to classify tumors into molecular subtypes as was
described by Carey et al. This classification defines subtypes
as follows: luminal A (ER+ and/or PR+ and HER2−),
luminal B (ER+ and/or PR+ and HER2+), HER2 subtype
(HER2+, ER− and PR−) and basal-like (ER−, PR−, HER2−,
CK5/6+ and/or EGFR+). When a tumor was negative for all
five markers it was denoted “unclassified” [23]. This sub-
classification is used as the immunohistochemical surrogate
of the subgroups detected by hierarchical clustering of gene-
expression analysis of breast cancers [5].
2.3 Scoring of immunohistochemistry
Scoring was performed by two observers (MRHvV, PJvD)
blinded to BRCA1 mutation status. For ER and PR the
percentage of positive nuclei was estimated, and cases with
>10% of stained cells were considered positive, according
to the Dutch guidelines [24]. HER-2/neu was scored
according to the DAKO system, considering only 3+ cases
as positive. EGFR and CK5/6 were reported positive if
clear membranous [25], respectively cytoplasmic staining
[26] was seen.
Since no consensus exists for ALDH1 scoring, we
scored both stromal and epithelial expression. Both inten-
sity and percentage of intratumoral epithelial ALDH1
positive cells were evaluated in invasive carcinomas.
Intensity was scored as 0 (absent), 1 (weak), 2 (moderate)
or 3 (strong). H-scores reflecting the overall epithelial
ALDH1 staining were calculated by multiplying the
intensity score with the percentage of positive cells. A
tumor was regarded positive if the H-score was 1 or above.
The intensity of intratumoral stromal expression was scored
from 0–4 as above in malignant tissues. The presence of
peritumoral stromal overexpression was scored separately
as present or absent.
2.4 Statistics
Discrete variables were compared by Chi-square test and
Fisher’s exact test and odds ratios (OR) were calculated
with 95% confidence intervals (95% CI). Normality of
continuous data was tested by Kolomogorov-Smirnov test
and groups were then compared by Students-T test or
Mann-Whitney U test for normally distributed and non-
parametric data, respectively.
In the case of comparisons between continuous and
discrete variables, correlation coefficients were calculated.
When features were associated (P<0.10) with both BRCA1
mutation status and the presence of ALDH1 staining,
bivariate statistical analysis of these possible confounders
took place by calculating ORs stratified for specific
subgroups (corrected by Mantel-Haenszel procedure). In
addition, multivariate analysis by means of logistic regres-
sion for all significant features was performed. All
statistical analyses were performed using SPSS 15.0.
3 Results
3.1 Baseline characteristics of the study cohort
The baseline characteristics of the cohort of patients with
invasive carcinomas are summarized in Table 2. Ductal
carcinoma was the most prominent histological subtype
accounting for 75.6% to 80.5% of tumors in the hereditary
and sporadic groups, respectively. In the BRCA1 related
group the frequency of medullary and metaplastic carcino-
mas was higher, whereas (ducto)lobular carcinoma were
more frequent in the sporadic group. In the sporadic group
tumors were most frequently of the luminal A type (73.2%).
Basal-like subtype was only present in 19.5% of the non-
carriers, in contrast with BRCA1 mutation carriers among
whom basal-like subtype was the most prominent subtype
(70.7%) (P<0.0005; OR 9.97; 95% CI 3.58–27.80). In both
groups tumors were most often of high grade, but grade 3
tumors were more frequent in BRCA1 related tumors
(75.6%) compared to sporadic tumors (58.5%) (P=0.10;
OR 2.20; 95% CI 0.85–5.65). This is consistent with the
median MAI, which was also significantly higher in the
BRCA1 group (22.0) compared to the sporadic group (14)
(P=0.007). Median tumor size was slightly higher in the
sporadic group (2.5 cm) compared to the group of mutation
Table 1 Primary antibodies, source, dilution, incubation times and methods of antigen retrieval used for immunohistochemistry
Primary antibody Clone Isotype Company Incubation time Dilution Antigen retrieval
ALDH1 44/ALDH Mouse BD transduction 60 min 1:100 Citrate pH 6, 100°C, 20 min.
CK5/6 D5/16Bu Mouse Chemicon 60 min 1:500 EDTA pH 9, 100°C, 20 min.
EGFR 2-18C9 Mouse Pharm Dx overnight, 4°C Pre-diluted Protein K, 5 min.
ER 1D5 Mouse DAKO 60 min 1:80 EDTA pH 9, 100°C, 20 min.
HER2 SP3 Rabbit Neomarkers 60 min 1:100 EDTA pH 9, 100°C, 20 min.
PR PgR636 Mouse DAKO 60 min 1:25 Citrate pH 6, 100°C, 20 min.
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carriers (1.9 cm) (P=0.04). A trend for more frequent
negative nodal status was seen in the BRCA1 group
(70.7%) compared to the sporadic group (46.9%)(P=
0.05). An expansive growth pattern was significantly more
often present in BRCA1 related tumors (52.5%) compared
to sporadic controls (23.7%) (P=0.009). Further, BRCA1
related tumors were more frequently negative for HER-2/
neu (n.s), ER (P<0.0005) and PR (P<0.0005).
3.2 ALDH1 expression in invasive carcinomas
ALDH1 expression in tumors showed wide variation,
ranging from weak to very strong expression and from
only a few positive cells, to a diffuse staining pattern in a
high percentage of positive cells (Fig. 1). Similar to benign
tissue, both stromal and epithelial cells expressed ALDH1
[18]. Epithelial ALDH1 expression was distributed ran-
domly over the tumor. However, for stromal expression a
specific peritumoral staining pattern was seen in some
cases. Data on epithelial and stromal expression are shown
in Table 3.
Significantly more tumors showed epithelial ALDH1
expression in the BRCA1 group (78.0%) compared to
sporadic breast cancer (41.5%) (P=0.001). Both the
intensity and the percentage of epithelial cells with ALDH1
expression were significantly higher in BRCA1 related
breast cancer. In this group, 19.5% showed strong ALDH1
expression, compared to none of the sporadic tumors (P=
0.005). Overall, the median percentage of positive cells was
0.0 in the sporadic group compared to 2.0 in the hereditary
group (P=0.01), and in the cases with ALDH1 expression,
the median percentage of positive cells was 10% in the
sporadic group compared to 5% in the hereditary group
(P=0.27)
Stromal ALDH1 expression within the tumor was
similarly high in both groups (strong expression in 43.9%
Sporadic group (n=41) BRCA1 group (n=41) P-value
N Percentage N Percentage
Histologic type Ductal 33 80.5% 31 75.6% n.s.
(Ducto)lobular 7 17.1% 3 7.3%
Medullary 0 0% 4 9.8%
Metaplastic 1 2.4% 3 7.3%
Molecular subtype Luminal A 30 73.2% 11 26.8% 0.0005
Luminal B 2 4.9% 0 0%
HER2+ 1 2.4% 0 0%
Basal-like 8 19.5% 29 70.7%
Unclassified 0 0% 1 2.4%
Histologic grade 1 5 12.2% 2 4.9% n.s.
2 12 29.3% 8 19.5%
3 24 58.5% 31 75.6%
Tumour size <2 cm 15 36.6% 21 56.8% n.s.
2–5 cm 21 51.2% 15 40.5%
>5 cm 5 12.2% 1 2.7%
Unknown 0 4
Lymph node status N0 15 46.9% 29 70.7% 0.05
N1 10 31.3% 11 26.8%
N2 5 15.6% 0 0%
N3 2 6.3% 1 2.4%
Unknown 9 0
Growth pattern Infiltrative 29 76.3% 19 47.5% 0.009
Expansive 9 23.7% 21 52.5%
Unknown 3 1
HER-2/neu status Negative 38 92.7% 41 100% 0.24
Positive 3 7.3% 0 0%
ER status Negative 11 26.8% 31 75.6% 0.0005
Positive 30 73.2% 10 24.4%
PR status Negative 14 35.0% 32 82.1% 0.0005
Positive 26 65.0% 7 17.9%
Unknown 1 2
Table 2 Characteristics of
BRCA1 related and sporadic
breast carcinomas
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of sporadic controls and 58.5% in hereditary cases; P=
0.14). However, the peritumoral stroma showed significant-
ly more frequent overexpression in the BRCA1 related
group (36.6%) compared to non-carriers (9.8%) (P=0.001)
(Fig. 1).
The presence of peritumoral and epithelial ALDH1
expression did not correlate with each other (P=0.73; OR
1.21; 95% CI 0.42–3.47) and in multivariate analysis both
were independent predictors of BRCA1 mutations status.
3.3 Correlation of ALDH1 with other characteristics
Epithelial ALDH1 expression in tumors correlated signif-
icantly with growth pattern (P=0.02; OR 3.29; 95% CI
1.19–9.09) and younger age (P=0.05; 95% CI 0.08–9.35).
In addition, a trend for correlation with PR negativity (P=
0.06; OR 0.41; 95% CI 0.16–1.04), ER negativity (P=0.08;
OR 0.45; 95% CI 0.18–1.10), basal-like subtype (P=0.08;
OR 2.26; 95% CI 0.91–5.65) and larger tumor size (P=
0.08) was found. Intratumoral stromal ALDH1 expression
did not correlate with other characteristics.
Peritumoral ALDH1 overexpression correlated with PR
negativity (P=0.002; OR 0.11; 95% CI 0.02–0.52), ER
negativity (P=0.001; OR 0.13; 95% CI 0.04–0.50), basal-
like subtype (P=0.004; OR 4.87; 95% CI 1.55–15.27) and
high MAI (P=0.009).
Since ER, PR, basal-like subtype and growth pattern
were associated with both mutation status and the presence
of epithelial ALDH1 expression, we performed stratified
analysis for basal-like subtype and growth pattern, and
estimated corrected ORs by Mantel-Haenszel procedure.
The OR, adjusted for basal-like subtype, was still signifi-
cant (ORadjusted 5.11; 95% CI 1.64–15.97; P=0.005) and
hardly differed from the crude OR (ORcrude 5.02). The
estimated OR adjusted for growth pattern was slightly
lower than the crude OR (ORadjusted 3.88; 95% CI 1.41–
10.69; P=0.009), but still significant. ER and PR were not
independently analyzed as possible confounders, because
they were constituents of basal-like subtype.
To correct for multiple confounders simultaneously, we
performed multivariate analysis, by including ALDH1
expression, basal-like subtype and growth pattern in a
stepwise logistic regression model. Hereby we estimated
the independent predictive value of these factors for
mutation status. In multivariate analysis only basal-like
subtype (P<0.0005) and the presence of epithelial ALDH1
Fig. 1 Expression of ALDH in
malignant breast tissues. Left:
Breast cancer in a BRCA1
mutated patient showing strong
peritumoral stromal (solid arrow)
and frequent intratumoral
epithelial expression (dashed
arrow). Right: Sporadic breast
cancer showing no peritumoral
stromal and hardly intratumoral
epithelial expression
Table 3 ALDH1 expression in BRCA1 related invasive breast carcinomas and sporadic controls
Sporadic group (n=41) BRCA1 group (n=41) P-value
N Percentage N Percentage
Intratumoral epithelial ALDH1 expression Negative 24 58.5% 9 22.0% 0.001
Positive 17 41.5% 32 78.0%
Intensity of epithelial ALDH1 expression Absent 24 58.5% 9 22.0% 0.005
Weak 8 19.5% 7 17.1%
Moderate 9 22.0% 17 41.5%
Strong 0 0% 8 19.5%
Intratumoral stromal ALDH1 expression Absent 2 4.9% 2 4.9% n.s.
Weak 9 22.0% 3 7.3%
Moderate 12 29.3% 12 29.3%
Strong 18 43.9% 24 58.5%
Peritumoral ALDH1 expression Absent 37 90.2% 26 63.4% 0.001
Present 4 9.8% 15 36.6%
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expression (P=0.005) were independent predictors of
BRCA1 mutation status, whereas growth pattern was no
longer of additional predictive value (P=0.25).
Since PR, ER, basal-like subtype and MAI correlated
significantly with both peritumoral ALDH1 expression and
BRCA1 mutation status, we performed univariate and
multivariate analysis to exclude confounders as above.
The OR adjusted for basal-like phenotype was no longer
significant (ORadjusted 2.65; 95% CI 0.77–9.04; P=0.12),
indicating that peritumoral ALDH1 expression and basal-
like subtype are not of independent predictive value for
BRCA1 mutation status. Because MAI was a continuous
variable it was only included in multivariate analysis. In a
logistic regression model only basal-like subclass (P<
0.0005), but not peritumoral ALDH1 expression (P=0.08)
and MAI (P=0.55), was of independent predictive value for
BRCA1 mutation status.
4 Discussion
This is the first study to evaluate ALDH1 expression in
breast cancers of BRCA1 mutation carriers and to compare
it to controls. We show that ALDH1 expression is
significantly higher in the epithelium and in the peritumoral
stroma in cancers of BRCA1 mutation carriers compared to
sporadic controls.
Intratumoral epithelial ALDH1 expression was clearly
more present in BRCA1 mutation carriers, implying that
this population indeed has an enlarged CSC component. We
find a somewhat higher frequency of epithelial expression
in the group of sporadic invasive carcinomas (40%), as was
described elsewhere (5–26%) [15, 27–29]. This might be
explained by the fact that we used age-matching to select
our sporadic controls. Hereby we possibly select a more
aggressive population then we would get by randomly
selecting breast cancers. This is also reflected by the high
frequency of grade 3 carcinomas (58.5%) in our sporadic
group. An additional problem, when comparing frequencies
between studies, is that there is no consensus on the scoring
method and the cut-off used for positivity. Most studies
score both intensity and percentage of positive cells and use
a cut off H >1, like we did, but higher thresholds (likely
leading to lower frequencies) have also been applied.
In both our study and literature a correlation between
intratumoral epithelial ALDH1 expression and basal-like
subtype and ER- and PR-negative receptor status was found
[15, 27]. We were unable to verify correlations between
ALDH1 in tumors and grade, HER2 overexpressing
subtype, CK5/6, CK14, [15] EGFR, p53, TOP2A [28],
Ki67 [29] and MAI [30] that were previously described.
This is probably due to the fact that we evaluated these
characteristics only in a small population (e.g.CK5/6,
EGFR) or not at all (e.g.CK14, p53, TOP2A). Furthermore,
we found a significant correlation between ALDH1
expression in tumors and expansive growth pattern and
younger age of onset.
There is no general consensus on the immunohistochem-
ical definition of threshold for CK5/6 positivity to use.
Korsching, E. et al, however, conclude that although a
variability of thresholds was used in different studies on
CK5/6 expression, they have very similar findings [31].
Therefore, the chosen threshold for CK5/6 positivity seems
of little importance for the outcome of our current study.
Rates of strong intratumoral stromal ALDH1 expression
were similar to literature [28] and significantly higher in
BRCA1 carriers than controls, as was peritumoral stromal
expression. Stromal ALDH1 expression is interesting
because of its association with BRCA1 mutation status
and outcome [28], but is not likely stem cell related,
because expression was also found in over 80% of normal
stroma tissue of non-carriers. The role of ALDH1 in
fibroblasts remains largely unexplored. Our results imply
that either BRCA1 is a regulator of stromal ALDH1
expression, or that stromal ALDH1 expression is a
physiologic response to (very early) carcinogenetic events.
It is plausible that stromal and epithelial ALDH1
expression reflect different processes in carcinogenesis,
since we could not find an association between epithelial
and peritumoral stromal ALDH1 expression. This hypoth-
esis is also supported by the seemingly contradictory
previous reports on the relation between ALDH1 expres-
sion and prognosis. Epithelial ALDH1 expression has been
associated with significantly decreased overall [15] and
disease free survival, grade and systemic metastasis [32]. In
addition, patients with an ALDH1 positive core needle
biopsy had a significantly lower rate of pathologic complete
response (pCR) after neo-adjuvant chemotherapy [33].
Contradictory with the association between epithelial
ALDH1 expression and poor prognosis, intratumoral
stromal ALDH1 expression correlated with good prognosis.
[28] An explanation for the different effects of stromal and
epithelial ALDH1 expression might be found in the
biological role ALDH1 plays in processes apart from its
potential role in stem cells and cellular differentiation. Both
a tumor suppressing and an oncogenic role have been
ascribed to retinoic acids (RA), the product of enzymatic
conversion of vitamin A by ALDH1. In the presence of
functional RA-receptor α (RARα), RA exhibits a growth
inhibitory pro-apoptotic role, whereas RA was shown to
promote cell growth and survival in the absence of
functional RARα [34]. These findings indicate that RA
can cause a diversity of effects, both pro- and anti-apoptotic
in specific situations, for instance different cell types (e.g.
stromal and epithelial cells). This diversity of working
mechanisms is in line with the independent associations for
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stromal and epithelial staining, we find in this study and
the contradictory associations with prognosis, found by
others.
Apart from its pure biological interest, our finding that
ALDH1 expression characterizes BRCA1 related breast
cancer might serve several clinical purposes. ALDH1 could
serve as a biomarker for BRCA1 mutation carriers. Easily
assessable biomarkers are necessary to recognize hereditary
cancers, because they can help to trigger analyzing family
history and to decide on mutation testing in patients at
borderline risk based on family history only. Tools that help
to select patients for screening are needed, since genetic
screening is time-consuming and expensive. Further, an
established phenotype can help to pin down the pathoge-
nicity of so called “unclassified variant” mutations. Since
intratumoral ALDH1 expression was the only characteristic
with additive predictive value independent of basal-like
phenotype for BRCA1 mutation status, adding ALDH1 to a
panel of IHC markers might significantly increase the
predictive value of the model.
In addition, ALDH1 might be a possible therapeutic
target in breast cancer. CSCs are considered relatively
therapy resistant [35]. Several promising ways to target the
ALDH1 CSC population have been identified. ALDH1 was
first identified to be a marker of hematopoietic stem cells
(HSCs). In CD34+CD38- HSCs it was shown that inhibiting
ALDH1 signaling increased the stem cell population. This
effect could be reversed by administration of exogenous all-
trans-retinoic acid (ATRA), which is used on a therapeutic
base in patients with acute promyelocytic leukemia
(APML) [36]. ATRA stimulates differentiation into mature
cells in these patients and treatment with ATRA in addition
to chemotherapy significantly improves survival [37]. Its
use in the treatment of other (solid) cancers has been
limited to date, due to systemic toxicity and the develop-
ment of resistance during carcinogenesis [38]. Recently it
was shown that ALDH1 regulates the differentiation of
breast CSC through retinoid signaling in a similar manner
as in HSCs [16]. Further, blocking the IL-8 receptor
CXCR1 with repertaxin has been shown to deplete the
ALDH1 positive CSC population in vitro and to decrease
the CSC population in human breast cancer xenografts,
retarding tumor growth and reducing metastasis [39]. Both
ATRA and repartaxin might enhance the effect of conven-
tional chemotherapy by specifically targeting CSCs and
sensitizing these relatively therapy resistant cells. This
therapy might be of specific use in BRCA1 related breast
cancer, since our results imply that these cancers have an
increased ALDH1 positive CSC population.
In conclusion, compared to sporadic controls, ALDH1
positive (cancer stem) cells and peritumoral expression
were significantly more frequent in BRCA1 related breast
cancer. ALDH1 tumor cell expression was an independent
predictor of BRCA1 mutation status. Thereby, ALDH1
might serve as a BRCA1 biomarker and therapeutic target.
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